Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group
Authors:
- Wenkui LiWLWenkui Li
- Faye Vazvaei‐SmithFVFaye Vazvaei‐Smith
- Gordon DearGDGordon Dear
- Jason BoerJBJason Boer
- Filip CuyckensFCFilip Cuyckens
- Daniela FraierDFDaniela Fraier
- Yuexia LiangYLYuexia Liang
- Ding LuDLDing Lu
- Heidi MangusHMHeidi Mangus
- Patricia MolinerPMPatricia Moliner
- Mette Lund PedersenMPMette Lund Pedersen
- Andrea A. RomeoARAndrea A. Romeo
- 12 March 2024
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 939-953
Abstract
The intent of this perspective is to share the recommendations of the International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on the fit‐for‐purpose metabolite bioanalysis in support of drug development and registration. This report summarizes the considerations for the trigger, timing, and rigor of bioanalysis in the various assessments to address unique challenges due to metabolites, with respect to efficacy and safety, which may arise during drug development from investigational new drug (IND) enabling studies, and phase I, phase II, and phase III clinical trials to regulatory submission. The recommended approaches ensure that important drug metabolites are identified in a timely manner and properly characterized for efficient drug development.Keywords
This publication has 68 references indexed in Scilit:
- Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White PaperClinical Pharmacology & Therapeutics, 2022
- Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018Clinical Pharmacology & Therapeutics, 2021
- Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsInvestigational New Drugs, 2021
- Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With RifabutinThe Journal of Clinical Pharmacology, 2020
- Mini‐Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME StudyCPT: Pharmacometrics & Systems Pharmacology, 2020
- Does In Vitro Potency Predict Clinically Efficacious Concentrations?Clinical Pharmacology & Therapeutics, 2020
- The Importance of the Human Mass Balance Study in Regulatory SubmissionsCPT: Pharmacometrics & Systems Pharmacology, 2019
- Strategies in quantitative LC‐MS/MS analysis of unstable small molecules in biological matricesBiomedical Chromatography, 2010
- Human radiolabeled mass balance studies: objectives, utilities and limitationsBiopharmaceutics & Drug Disposition, 2009
- A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detectionRapid Communications in Mass Spectrometry, 2007